Diakonos Oncology biotech firm developing dendritic cell vaccines targeting difficult cancer types.
Diakonos Oncology has raised $7.0M in total funding. The most recent round was Grant. The last funding was announced in December 2025.
Diakonos Oncology's investors include Baylor College of Medicine, Cancer Prevention and Research Institute of Texas, Restem Group, Brain Tumor Investment Fund, Buttonwood Titan QC Fund.
Diakonos Oncology is headquartered in Houston, United States.
Diakonos Oncology biotech firm developing dendritic cell vaccines targeting difficult cancer types.
Diakonos Oncology is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Diakonos Oncology — Funding & Investors." VCBacked, December 10, 2025, https://www.vcbacked.co/company/diakonos-oncology. Accessed September 30, 2026.
VCBacked. (2025). Diakonos Oncology — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/diakonos-oncology
{{cite web |title=Diakonos Oncology — Funding & Investors |url=https://www.vcbacked.co/company/diakonos-oncology |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated